Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741891 | 0.89 | KDR (0.75) | KDR | |
| SCHEMBL5742011 | 0.85 | KDR (1.00) | KDR | |
| SCHEMBL6897451 | 0.82 | KDR (0.93) | KDR | |
| SCHEMBL5743045 | 0.81 | KDR (0.75) | KDR | |
| SCHEMBL5741947 | 0.80 | KDR (0.71) | KDR | |
| SCHEMBL6180725 | 0.79 | KDR (0.71) | KDR | |
| SCHEMBL5743358 | 0.77 | KDR (0.48) | KDR | |
| SCHEMBL6178074 | 0.76 | KDR (1.00) | KDR | |
| SCHEMBL5742451 | 0.75 | KDR (0.48) | KDR | |
| SCHEMBL6179134 | 0.75 | KDR (1.00) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404672-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-01-18 | — | — | EP | claimed |
| US-6875767-B2 | (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-04-05 | — | — | US | claimed |
| EP-1404672-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | claimed |
| WO-2003000687-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-1404672-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-6875767-B2 | (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1404672-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003000687-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100567-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.